Product Description
Avacincaptad pegol, a polyethylene glycol-conjugated oligonucleotide, is a potent C5 inhibitor delivered via a 100 µl intravitreal injection. (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2772902)
Mechanisms of Action: C5 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: Breakthrough Therapy - Geographic AtrophyFast Track - Geographic Atrophy|Macular DegenerationPriority Review - Geographic Atrophy *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IVERIC bio
Company Location: NEW YORK NY 10001
Company CEO: Glenn P. Sblendorio
Additonal Commercial Interests: DelSiTech
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Geographic Atrophy|Macular Degeneration
Phase 2: Stargardt Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STGD1 | P2 |
Active, not recruiting |
Stargardt Disease|Macular Degeneration |
2025-04-30 |
24% |
| STGD1 | P2 |
Active, not recruiting |
Stargardt Disease|Macular Degeneration |
2025-04-30 |
24% |
| GATHER2 | P3 |
Active, not recruiting |
Geographic Atrophy|Macular Degeneration |
2025-03-31 |
|
| GATHER2 OLE | P3 |
Active, not recruiting |
Geographic Atrophy |
2025-03-21 |
|
| Complement C5 Inhibitor | P3 |
Completed |
Geographic Atrophy|Macular Degeneration |
2022-07-25 |